Skip to content

Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices.

Gisela Lima, Carla Soares, Marta Teixeira, Miguel Castelo-Branco

British journal of clinical pharmacology December 1, 2024 DOI: 10.1111/bcp.16264 via PubMed

Summary

AI-generated from the abstract

Psychedelics are being explored for physical and mental health applications beyond psychiatry, including chronic pain, palliative care, and neuroprotection in ischemia. This article reviews dimethyltryptamine (DMT) and ayahuasca pharmacology, effects, safety, and toxicity, and details the anaesthetist's role in clinical and experimental research—covering participant screening, dosing sessions, adverse effect management, and toxicity treatment. It draws on a current neuroimaging study protocol. The authors argue that anaesthetists are uniquely positioned to manage psychedelic therapy in medically complex, polymedicated patients, but note that non-mental medical applications remain underexplored.

Study at a glance

Characteristics Review Peer reviewed
Population Patients with comorbidities, functional limitations, polymedicated
Topics Ayahuasca DMT
Keywords Psychedelic research Psychedelic toxicity Serotonin toxicity
Citations 4
Key finding Anaesthetists can play a central role in administering psychedelics for non-mental medical conditions, but protocols for such applications are lacking.

Abstract

Recent years have witnessed an unprecedented increase in the search for the use of psychedelics in improving physical and mental health. Anaesthesia has evolved since very early times, born from the need to eliminate pain and reduce suffering and there are reports of the use of anaesthetics to achieve mystical states since the nineteenth century. Nowadays, the renaissance of psychedelics in anaesthesia has been inspired by their potential in the treatment of chronic pain syndromes, palliative care and in the emergency department and pre-hospital care with the administration of psychedelics in cases of ischaemia, given their potential in neuroprotection. Although there are already some published protocols for the administration of psychedelics in patients with mental illness, little has been addressed concerning non-mental medical applications. In this sense, in patients with multiple comorbidities, functional limitations and polymedicated, the anaesthetist may play a fundamental role, not only in clinical practice, but also in translational research. This article focuses on the description of psychedelics, with a particular focus on dimethyltryptamine (DMT) and ayahuasca pharmacology, effects, safety and toxicity. A detailed description of the role of the anaesthetist in clinical and experimental research is provided, from participant's screening to preparation and dosing session, expected adverse effects and how to manage them, based on the protocol and standard procedures of a current study with neuroimaging during the psychedelic experience. Specific considerations regarding the management of psychedelic toxicity are also provided as well as future directions for safe psychedelic use in clinical practice.

Explore topics

Comments

No comments yet.

Log in to comment